OncoAlert

🫁Now that #ELCC26 is Over, we've got you covered! The latest OncoAlert Special Edition Newsletter is out — our picks of the top trials: REGISTERE HERE 👉 buff.ly/7Jlzp0V or OncoAlert360.com Covering 🔬 Setidegrasib — KRAS G12D degrader with concurrent NEJM publication 🎯 TOP — osimertinib + chemo in EGFR/TP53 co-mutant NSCLC 💊 Beamion LUNG-1 — zongertinib in HER2-mutant NSCLC 💊 OptiTROP-Lung03 — sac-TMT final OS data 💊 PRESERVE-003 — gotistobart post-PD-(L)1 squamous NSCLC 💊 Iza-bren + serplulimab — remarkable ORR in ES-SCLC 🧬 LATIFY — a negative trial we need to talk about 🧬 i-TIMES — does ICI timing matter? 🎯 NorthStar — who benefits from local consolidation? Written for oncologists, by oncologists. 👉 Register at OncoAlert360.com Ping #LungCancer Faculty @GlopesMd @jillfeldman4 @EGFRResisters @UmbertoMalapel1 @isliquidbiopsy @BRicciutiMD @UOzkerim @gerryhanna @acampsmalea @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago @matteolambe @Icro_Meattini @GlopesMd @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @peters_solange @christine_lovly @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo @MartinReck2 @Latinamd @JulienMazieres @nataliagandur

The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 3️⃣ #GU26 Presentation by Dr. Brian Rini: Year in Review in Renal Cell Carcinoma #KidneyCancer REGISTER HERE TO WATCH: buff.ly/FaS5Cb6 Brian Rini’s 2025 year-in-review highlights real progress—and ongoing challenges—in kidney cancer Adjuvant pembrolizumab remains the global standard, with durable DFS & OS benefits, while other adjuvant IO trials were negative. New RAMPART data suggest durvalumab + tremelimumab may benefit only the highest-risk patients, underscoring the need for better risk stratification 📊. KIM-1 has emerged as a promising blood-based prognostic biomarker (prospective validation needed ). In refractory disease, combination strategies show greater activity but higher toxicity, with survival data still maturing. In non–clear cell RCC, IO doublets and belzutifan-based combinations are reshaping standards of care 🚀 GU Oncology Colloquium Faculty @brian_rini 🇺🇸 @tompowles1 🇬🇧 @declangmurphy 🇦🇺 @KidneyCancer🇺🇸 @salvolarosa @silkegillessen 🇨🇭 @RenuEapen🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @DrJaVallejo 🇪🇸 @realbowtiedoc Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg Our Collaborators @APCCC_Lugano @gu_onc @Uromigos @montypal @crisbergerot @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @cdanicas @AOmlin

The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY3️⃣ #GU26 Presentation by Dr. Salvatore La Rosa 🇺🇸 of Kidney Cancer Association: Year in Review REGISTER HERE TO WATCH: buff.ly/FaS5Cb6 Kidney cancer remains a highly unmet need, especially in today’s challenging funding environment—and meaningful progress will require stronger alignment across the entire ecosystem. At the KCA, we work side-by-side with medical professionals, researchers, clinicians, industry partners, funders, and patients to create the synergies that move the field forward faster—through education, convening, research support, and community building. We invite you to join us across our programs and events to learn, share data and ideas, collaborate on solutions, and be part of a global kidney cancer community that is committed to accelerating scientific progress—together. #KidneyCancer GU Oncology Colloquium Faculty @brian_rini 🇺🇸 @tompowles1 🇬🇧 @declangmurphy 🇦🇺 @KidneyCancer🇺🇸 @salvolarosa @silkegillessen 🇨🇭 @RenuEapen🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @DrJaVallejo 🇪🇸 #OncoAlertAF @acampsmalea @BRicciutiMD @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @DrRishabhOnco @Onco_Cifu88 @PaulJiL Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg Our Collaborators @APCCC_Lugano @gu_onc @Uromigos @montypal @crisbergerot @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @cdanicas @AOmlin

Our Coverage from #GU26 Continues We are proud to have Dr. @Clara__Steiner 🇩🇪@DanaFarber 🇺🇸share with you her poster Presented in San Francisco Pilot phase I trial of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma. This pilot phase I study evaluated implantable microdevices (IMDs) delivering microdoses of multiple drugs directly into renal cell carcinoma tumors. In 10 patients, CT-guided IMD placement before surgery proved safe and feasible, with successful tissue analysis in most cases. The approach revealed spatial, drug-specific effects on apoptosis, proliferation, and immune composition, demonstrating the potential of IMDs to guide personalized therapy selection while avoiding systemic toxicity. #KidneyCancer @DrChoueiri @MattMossanen @MichelleDunno17 @bergsa83 @MikeSerzanMD @BradMcG04 @srviswanathan @stusilverman @VincentWenxinXu @motzermd @DrIacovelli @DrYukselUrun @elena_verzoni @tompowles1 @montypal @crisbergerot @DrDanielHeng @apolo_andrea @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @drenriquegrande @BraunMDPhD @cdanicas @brian_rini @AUC3_Official @nataliagandur @MarcMachaalani @Mustafajsalehmd @NazliDizman @DrYukselUrun @yekeduz_emre @WeiweiBian @ReneeSaliby @eddy_saad @marc_eid @pablombarrios @WDKhatoun @Jad_El_Masri @lilli_ash @RashadNawfal @RazaneHChehade @elioibrahim8 @NafehGaelle @shaye_carver @zeyun_lu @SylvanBacaLab

The #OncoAlertColloquium 2026 Breast Malignancies🚨 #EBCC15 Presentation by Dr. Matteo Lambertini 🇮🇹 : ER+ Early #BreastCancer REGISTER HERE TO WATCH👉 buff.ly/4eLekQf ER+ Early #BreastCancer — What changed in clinical practice in 2025 📊 🔹 Adjuvant CDK4/6i + ET: More solid evidence — including the first OS data — now supports use in high-risk HR+/HER2- EBC ✅ 🔹 Oral SERDs enter early disease: First positive data with giredestrant in HR+/HER2- EBC, opening the door to new endocrine strategies 🔹 Risk stratification matters (more than ever): Long-term data reinforce tailoring adjuvant ET, including OFS use, in premenopausal patients 🎯 🔹 Quality of life & survivorship: Growing role for non-hormonal pharmacologic options for VMS, with reassuring oncofertility safety data from POSITIVE & PREFER A year of meaningful progress — from outcomes to survivorship — in ER+ early disease #BreastCancer @hoperugo 🇺🇸 @matteolambe 🇮🇹 @Icro_Meattini 🇮🇹 Dr. Roberto Salgado 🇧🇪 @ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @itrisabel 🇪🇸 @ESSOnews @ElisaAgostinett 🇧🇪 @RebeccaDSing 🇸🇬 @LazarPo31787807 🇷🇸 @aftimosp @jesusanampa @StoverLab @curijoey @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JaniceTNBCmets @Prof_Nadia_H @MammaMiaMagazin @itrisabel #OncoAlertAF @nataliagandur @acampsmalea @FernandoOnco @to_be_elizabeth @bavilima @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @DrRishabhOnco @Onco_Cifu88 Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

🚨 CAPOX in CRC + diverting stoma: think twice 📊 n=87 ⚠️ Hospitalization: 35% vs 18% (vs FOLFOX) ⚠️ Early, mainly GI toxicity 💡 Same drugs, very different tolerability 👉 mFOLFOX6 may be the safer adjuvant choice here 🔗 doi.org/10.1200/OP-25-… @JCOOP_ASCO @GrupoTTD @myESMO

KRASG12C inhibition meets EGFR feedback Block both KROCUS trial. Fulzerasib + cetuximab in 1L NSCLC (phase 1b/2) in @TheLancetOncol ORR 69%, PFS 12.5 mo Rational combination. Promising early signal thelancet.com/journals/lanon… @OncoAlert

How might systemic therapy reshape the management of MIBC? Laura Bukavina, Tyler Stewart, and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC, including the potential omission of cystectomy in patients who achieve a clinical complete response. Listen now! 🎧 GUOnc: guoncologynow.com/podcast/episod… 🎧 Apple Podcasts: podcasts.apple.com/us/podcast/the… 🎧 Spotify: #Uromigos" target="_blank" rel="nofollow noopener">open.spotify.com/episode/09rjfU… #GUOncology

Well deserved recognition for an essential member of the oncology care team!! @HOPArx @KoontzOncology @OncoAlert

In this important article resistance to next-generation SERDs in ER+/HER2− metastatic breast cancer is primarily driven by loss of luminal lineage identity, leading to reduced ERα dependence and activation of alternative proliferative pathways. Heterogeneous responses: •~30–50% of patients progress early (≤2 months) •Others derive prolonged benefit (>2 years) •Resistance occurs independently of ESR1 mutation status •Stronger association with: Prior CDK4/6 inhibitor exposure and baseline low ERα activity @OncoAlert @jhaveri_komal 👉 nature.com/articles/s4146…

Our work out of #JavelinRenal101 in @OncJournal remains relevant and brings wealth of info to designing next clinical trials for VEGF/IO (and even new drugs): A notable proportion of patients have high baseline and on-therapy cardiac. However, NO association between elevation in cardiac biomarkers and incidence of major adverse cardiac events ! cc: @CardioOncology academic.oup.com/oncolo/advance…

Video Now available by COR2ED 🫁 Select datopotamab deruxtecan-associated adverse events Access Here👉 buff.ly/puNYJsp Join Aaron Lisberg as he highlights key insights from recent publications on managing datopotamab deruxtecan (Dato-DXd)–associated adverse events. In this short video, discover practical strategies to proactively monitor and manage mucositis, nausea, and ocular toxicities. Access downloadable infographics and a treatment checklist to support patient care, enhance safety, and optimize outcomes in advanced solid tumors treated with Dato-DXd. #ELCC26 #LungCancer

New findings support hypomethylating agents/venetoclax as an effective induction strategy in selected younger patients with #AML and provide a rationale for prospective randomized trials comparing this approach with IC-based regimens. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #LeuSM

Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #BreastCancer after endocrine progression. ja.ma/47zByON

FAP-PET may help de-risk adrenal lesions and prevent unnecessary aggressive surgery when FDG can be misleading. See this case series of benign adrenocortical oncocytic neoplasms with paired FDG and FAP PET/CT scans. jnm.snmjournals.org/content/jnumed…

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. ja.ma/4167rLa

Planning to present Phase III trial data at a conference? Consider publishing in CA. Rapid review is available for accepted proposals to allow for simultaneous publication with conference proceedings. Submission details: acsjournals.onlinelibrary.wiley.com/doi/toc/10.332… @OncoAlert

When (& for whom) should we “go beyond” systemic therapy in stage IV NSCLC? Our patient-friendly @JAMAOnc publication reviews LCT patient selection + clinical context. 🔗 jamanetwork.com/journals/jamao… Rule of 3: Right patient. Right time. Right team. @maraantonoff @UTMDAnderson

Our paper is online @JTOonline Molecular Profiling across 80,000 Patients with Lung Cancer. A robust demonstration that we need to test all patients with NSCLC & ALL histologies and open the door for nomenclature change. jto.org/article/S1556-… @Al3ssandroRusso @OhioStateMedOnc

🧠📊 IO in GEA: who truly benefits? (Editorial) ✔️ CPS ≥5 → durable OS benefit → 5y OS 16% vs 6% ⚠️ CPS 1–4 → ❌ no OS benefit (HR 1.10) 👉 Signal emerges only from CPS ≥5–9 ⚠️ ↑ G3–4 toxicity (17% vs 10%) 💡 Selection + toxicity matter 🔗 doi.org/10.1016/j.anno… @OncoAlert

Getting the right measure: Gait speed assessment and outcomes in older patients with cancer geriatriconcology.net/article/S1879-… @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #GaitSpeed #GaitSpeedReserve #PhysicalFunctioning